Alzheimer’s disease (AD) is increasingly understood not only as a clinical syndrome, but as a biological disease process that begins years before memory loss or other cognitive symptoms become apparent. Because amyloid beta (Aβ) deposition, tau pathology, neuroinflammation, synaptic dysfunction, and neuronal injury may develop long before a patient receives a clinical diagnosis, AD biomarker testing is becoming central to earlier and more precise assessment.
This has changed the way researchers, clinicians, and drug developers think about AD. Traditional diagnosis relied heavily on symptoms, cognitive testing, and exclusion of other causes of dementia. Today, biomarkers are helping move the field toward earlier detection, more precise disease staging, better patient selection for clinical trials, and more objective monitoring of therapeutic response, shifting the field from symptom-based assessment to biology-based evaluation. In this context, the central question is how to choose the right biomarkers and testing strategy for each scientific and clinical need.
The Shift Toward Biomarker-Driven AD Assessment
The 2024 revised diagnostic criteria issued by the Alzheimer’s Association reinforced the central role of biomarkers in defining and staging AD. Rather than viewing biomarkers as optional supporting evidence, the field is increasingly using them to identify the underlying biology of disease, setting up a closer look at the main biomarker categories.
Core AD biomarkers generally fall into categories that reflect key pathological features. Amyloid-related biomarkers, such as cerebrospinal fluid (CSF) Aβ42/40 ratio and amyloid PET imaging, help identify Aβ pathology. Tau-related biomarkers, including phosphorylated tau species such as p-tau181, p-tau217, and p-tau231, provide insight into tau pathology and disease progression. Other biomarkers, including neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), MRI, and FDG-PET, may reflect neuronal injury, neurodegeneration, or neuroinflammation.
Just as importantly, biomarkers can help distinguish AD from non-AD co-pathologies, such as vascular brain injury or α-synuclein-related disease. This matters because cognitive decline in older adults is often biologically complex, and mixed pathology can complicate both diagnosis and therapeutic development, underscoring the importance of biomarker clarity.
CSF Biomarkers: High-Value Evidence Close to the CNS
CSF biomarkers remain among the most informative tools for evaluating AD biology because CSF is in direct exchange with the extracellular environment of the central nervous system. CSF Aβ42, Aβ42/40 ratio, total tau, and phosphorylated tau have shown strong concordance with amyloid PET and can support early diagnosis, differential diagnosis, and clinical trial enrollment.
The strength of CSF testing lies in its proximity to the brain and its ability to reflect multiple dimensions of AD pathology. However, lumbar puncture is more invasive than blood collection, which can limit its use in broad screening or longitudinal monitoring. For this reason, CSF testing is often most valuable when high diagnostic confidence is needed, such as in confirmatory testing, clinical trial stratification, or evaluation of patients with atypical presentations.
Blood-Based Biomarkers: Expanding Access and Scalability
Blood-based biomarkers are one of the most important developments in the AD field. Compared with CSF collection or PET imaging, blood sampling is less invasive, more scalable, and more practical for repeated testing. This makes plasma biomarkers attractive for screening, epidemiological studies, patient enrichment, and longitudinal monitoring in clinical trials.
Plasma Aβ42/40 may help identify amyloid pathology, although the magnitude of change in blood can be small and analytically challenging. Plasma p-tau biomarkers, particularly p-tau217, have shown especially strong promise for distinguishing amyloid-positive and tau-positive disease states. Because p-tau217 appears closely associated with AD pathology, it is emerging as one of the most useful blood-based biomarkers for AD research and potentially for future clinical workflows.
Other blood-based markers can add complementary information. NfL may reflect axonal injury but is not specific to AD. GFAP may provide insight into astrocytic activation and neuroinflammation. Used together, these markers can help build a more complete picture of disease biology, especially when combined with imaging, CSF, cognitive, and clinical data.
Emerging Biomarkers Add Biological Context
Beyond Aβ and tau, the AD biomarker landscape is expanding rapidly. Neurogranin may provide information about synaptic injury. NfL can help assess neuroaxonal damage. GFAP and YKL-40 may reflect inflammatory or glial responses. MicroRNAs and other molecular markers are also being explored for their potential to detect disease states, monitor progression, or predict therapeutic response.
These emerging biomarkers are unlikely to replace core AD biomarkers in the near term. Instead, their greatest value may be in adding biological context, especially in drug development. As AD therapeutics become more targeted, developers will need biomarker strategies that can confirm target engagement, identify responsive patient subgroups, and monitor downstream pharmacodynamic effects.
Matching the Testing Platform to the Scientific Question
No single technology platform is ideal for every AD biomarker application. Platform selection should depend on the sample type, expected analyte concentration, required sensitivity, throughput needs, study phase, and intended use of the data.
ELISA remains useful for established biomarkers, particularly in CSF, and can be cost-effective for screening or early-stage assay work. Automated immunoassay platforms, including chemiluminescent and electrochemiluminescent systems, offer stronger standardization and higher throughput, making them well-suited for larger studies or settings where reproducibility across sites is important.
Ultra-sensitive digital immunoassay platforms, such as single-molecule array technology, are especially valuable for low-abundance blood-based biomarkers, including p-tau species and NfL. These platforms can support translational research where small concentration changes may be biologically meaningful. Mass spectrometry, including immunoprecipitation-mass spectrometry, can offer high molecular specificity and may be useful when detailed peptide-level information is needed, such as Aβ peptide profiling or characterization of tau phosphorylation.
A Strategic Approach to AD Biomarker Testing
As AD research moves toward earlier intervention and more targeted therapies, biomarker testing strategies must become more precise, standardized, and fit-for-purpose. A strong biomarker plan should consider not only which markers to measure, but also when to measure them, which sample type to use, which platform is appropriate, and how results will support decision-making. The goal is to align each test with the specific scientific question it is meant to answer.
In drug development, the most effective strategies often combine multiple biomarker types: core AD biomarkers to confirm disease biology, exploratory biomarkers to understand mechanisms, and pharmacodynamic markers to evaluate treatment effects. In clinical research, standardization of collection, handling, assay validation, and data interpretation will be essential for generating reliable, comparable results.
The future of AD biomarker testing will likely be defined by greater use of blood-based assays, improved harmonization across platforms, and more integrated biomarker panels that reflect the complexity of disease. As these tools continue to mature, their value will depend on how closely they align with the clinical or research question, and they will play an increasingly important role in advancing earlier diagnosis, more efficient clinical trials, and more precise therapeutic development for Alzheimer’s disease.
